Protalix BioTherapeutics, Inc.
PLX · AMEX
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 47.64M | 28.05M | -13.01M | -14.93M | -0.31 |
| 2023 FY | 65.49M | 42.51M | 10.46M | 8.31M | 0.12 |
| 2024 FY | 53.40M | 29.08M | 3.92M | 2.93M | 0.04 |
| 2025 FY | 52.74M | 25.24M | -5.50M | -6.60M | -0.08 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 55.79M | 66.43M | 17.11M | 33.47M | -10.64M |
| 2023 FY | 84.43M | 50.87M | 23.63M | 27.69M | 33.57M |
| 2024 FY | 73.42M | 30.21M | 19.76M | 5.53M | 43.21M |
| 2025 FY | 82.35M | 34.12M | 14.68M | 8.32M | 48.23M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -25.00M | -628.00K | -25.63M | — | -21.87M |
| 2023 FY | -1.32M | -1.15M | -2.47M | — | 6.52M |
| 2024 FY | 8.67M | -1.28M | 7.39M | — | -3.87M |
| 2025 FY | -11.99M | -1.64M | -13.63M | — | -4.38M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 66.41M | 82.77M | — | — | — |
| 2023 FY | 120.17M | 124.23M | — | — | — |
| 2024 FY | 136.36M | 122.12M | — | — | — |
| 2025 FY | 141.38M | 135.02M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 15.66M | 9.79M | 1.17M | 164.00K | 0.00 |
| 2025 Q3 | 17.85M | 9.53M | 2.13M | 2.36M | 0.03 |
| 2025 Q4 | 9.12M | 4.50M | -4.66M | -5.50M | -0.07 |
| 2026 Q1 | 33.75M | 29.62M | 21.15M | 18.32M | 0.23 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 78.49M | 28.58M | 17.90M | 5.35M | 49.90M |
| 2025 Q3 | 82.26M | 29.36M | 13.65M | 8.18M | 52.91M |
| 2025 Q4 | 82.35M | 34.12M | 14.68M | 8.32M | 48.23M |
| 2026 Q1 | 102.34M | 35.11M | 41.71M | 8.48M | 67.23M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -5.23M | -431.00K | -5.66M | — | -1.56M |
| 2025 Q3 | -3.73M | -498.00K | -4.23M | — | -4.25M |
| 2025 Q4 | 2.03M | -403.00K | 1.63M | — | 1.03M |
| 2026 Q1 | 22.03M | -761.00K | 21.26M | — | 26.32M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 116.42M | 103.88M | — | — | — |
| 2025 Q3 | 176.01M | 170.54M | — | — | — |
| 2025 Q4 | 141.38M | 135.02M | — | — | — |
| 2026 Q1 | 173.27M | 140.04M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |